RxDoctor Payments Data

Erik Eways, MD

Interventional Cardiology · Mobile, ALNPI 1043266919

Payments from drug & device makers

$954in general payments, 2019–2025

Across 26 payments — averaging $36.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$455
  • Biotronik Inc.$137
  • Abbott$81
  • Amgen$67
  • Boehringer Ingelheim$59
  • Merck$50
  • plus $105 from 6 others

What the payments were for

  • Food & beverage$954100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$954 in reported general payments places this provider in the 5th percentile of 109 interventional cardiology providers in Alabama.

See all interventional cardiology providers in Alabama

Medicare billing

Part B allowed, 2024
$221,892
Medicare patients
711
Services billed
1,890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban251$204,921
EntrestoSacubitril/Valsartan65$87,197
XareltoRivaroxaban66$59,796
Carvedilol338$2,885
Atorvastatin Calcium197$2,300
Losartan Potassium190$2,267
Verapamil SrVerapamil Hcl18$2,225
Midodrine Hcl16$2,136
Metoprolol Succinate162$1,874
Hydralazine Hcl78$1,305
Rosuvastatin Calcium102$1,130
Amiodarone Hcl44$1,092
Amlodipine Besylate156$1,025
Pravastatin Sodium29$894
ClopidogrelClopidogrel Bisulfate78$815

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$13$87,19765 claims
Johnson & JohnsonXarelto$12$59,79666 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 109 interventional cardiology providers in Alabama.

Other interventional cardiology in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →